These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Shinnar S; Pellock JM; Conry JA Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174 [TBL] [Abstract][Full Text] [Related]
47. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai YM; Yu SC; Lin CC J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949 [TBL] [Abstract][Full Text] [Related]
48. Effectiveness of melatonin in tardive dyskinesia. Castro F; Carrizo E; Prieto de Rincón D; Rincón CA; Asián T; Medina-Leendertz S; Bonilla E Invest Clin; 2011 Sep; 52(3):252-60. PubMed ID: 21950196 [TBL] [Abstract][Full Text] [Related]
49. Levetiracetam in tardive dyskinesia. Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471 [TBL] [Abstract][Full Text] [Related]
50. Is adjunctive open-label zonisamide effective for bipolar disorder? Ghaemi SN; Shirzadi AA; Klugman J; Berv DA; Pardo TB; Filkowski MM J Affect Disord; 2008 Jan; 105(1-3):311-4. PubMed ID: 17586053 [TBL] [Abstract][Full Text] [Related]
51. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. Iwata Y; Irie S; Uchida H; Suzuki T; Watanabe K; Iwashita S; Mimura M J Neurol Sci; 2012 Apr; 315(1-2):137-40. PubMed ID: 22285275 [TBL] [Abstract][Full Text] [Related]
52. Zonisamide for the treatment of Parkinson's disease. Miwa H Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006 [TBL] [Abstract][Full Text] [Related]